Abstract
Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has been associated with the worst patient survival rates of the various acute leukemias. Imatinib mesylate is a novel therapeutic agent that targets the BCR-ABL tyrosine kinase, the molecular abnormality associated with Ph+ ALL. The combination of imatinib with chemotherapy has led to improved and durable treatment responses in adult patients with Ph+ ALL, including the elderly population. Hematopoietic stem cell transplantation has also integrated imatinib into its transplant strategies, with early data suggesting improved progression-free survival without clearly identifiable augmented toxicity. Second-generation tyrosine kinase inhibitors offer potentially even greater improvements on these excellent imatinib-associated outcomes. This review addresses the evolution of the management of Ph+ ALL and is intended to assist in the description of its new natural history.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 343-351 |
| Number of pages | 9 |
| Journal | Current Oncology Reports |
| Volume | 8 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 2006 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Philadelphia chromosome-positive acute lymphoblastic leukemia : Impact of imatinib treatment on remission induciton and allogeneic stem cell tranplantation. / Kovacsovics, Tibor; Maziarz, Richard.
In: Current Oncology Reports, Vol. 8, No. 5, 09.2006, p. 343-351.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Philadelphia chromosome-positive acute lymphoblastic leukemia
T2 - Impact of imatinib treatment on remission induciton and allogeneic stem cell tranplantation
AU - Kovacsovics, Tibor
AU - Maziarz, Richard
PY - 2006/9
Y1 - 2006/9
N2 - Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has been associated with the worst patient survival rates of the various acute leukemias. Imatinib mesylate is a novel therapeutic agent that targets the BCR-ABL tyrosine kinase, the molecular abnormality associated with Ph+ ALL. The combination of imatinib with chemotherapy has led to improved and durable treatment responses in adult patients with Ph+ ALL, including the elderly population. Hematopoietic stem cell transplantation has also integrated imatinib into its transplant strategies, with early data suggesting improved progression-free survival without clearly identifiable augmented toxicity. Second-generation tyrosine kinase inhibitors offer potentially even greater improvements on these excellent imatinib-associated outcomes. This review addresses the evolution of the management of Ph+ ALL and is intended to assist in the description of its new natural history.
AB - Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has been associated with the worst patient survival rates of the various acute leukemias. Imatinib mesylate is a novel therapeutic agent that targets the BCR-ABL tyrosine kinase, the molecular abnormality associated with Ph+ ALL. The combination of imatinib with chemotherapy has led to improved and durable treatment responses in adult patients with Ph+ ALL, including the elderly population. Hematopoietic stem cell transplantation has also integrated imatinib into its transplant strategies, with early data suggesting improved progression-free survival without clearly identifiable augmented toxicity. Second-generation tyrosine kinase inhibitors offer potentially even greater improvements on these excellent imatinib-associated outcomes. This review addresses the evolution of the management of Ph+ ALL and is intended to assist in the description of its new natural history.
UR - http://www.scopus.com/inward/record.url?scp=33748360705&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748360705&partnerID=8YFLogxK
U2 - 10.1007/s11912-006-0056-y
DO - 10.1007/s11912-006-0056-y
M3 - Article
C2 - 16901395
AN - SCOPUS:33748360705
VL - 8
SP - 343
EP - 351
JO - Current Oncology Reports
JF - Current Oncology Reports
SN - 1523-3790
IS - 5
ER -